A recent report highlights the importance of using rivaroxaban cautiously in morbidly obese.
Your search for Warfarin returned 107 results
The Food and Drug Administration (FDA) is warning patients and caregivers not to use test strips from previous owners or ones not authorized for sale in the US.
Results from a real-world study evaluating rivaroxaban (Xarelto; Janssen) in newly diagnosed patients with nonvalvular atrial fibrillation (NVAF) were presented at the American College of Cardiology’s (ACC) 68th Annual Scientific Session.
Terrific Care/Medex Supply had purchased these test strips (which were distributed by Roche Diagnostics outside the country) from an unknown source, imported and sold them in the US.
To investigate an appropriate dosing strategy for 4F-PCC (Kcentra; CSL Behring) in obese patients, the authors conducted a retrospective analysis comparing the reversal of warfarin using adjusted (N=28) vs actual body weight (N=50).
To compare the incidence of hospitalization for upper GI tract bleeding, researchers used US Medicare beneficiary files to identify a cohort of patients that were ≥30 years old who initiated oral anticoagulation therapy with apixaban, dabigatran, rivaroxaban, or warfarin, with or without PPI cotherapy.
Over 1.1 million packages of test strips distributed from January 12, 2018 to October 29, 2018 are being recalled.
In 2017, a Work Group was assembled to conduct a systematic review of 3HP regimen studies published between January 2006 to June 2017, specifically looking at outcomes in children, individuals with HIV/AIDS, and those who self-administered treatment.
For this review, researchers performed an extensive literature search for studies and cases where an adverse drug reaction occurred likely due to an interaction between an herbal and a prescribed medicine.
The FDA analysis evaluated the safety of Xarelto in people with nonvalvular atrial fibrillation who initiated Xarelto or warfarin from November 2011 to April 2015.